Vasomotor symptoms resulting from natural menopause: a systematic review and network meta‐analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause

  title={Vasomotor symptoms resulting from natural menopause: a systematic review and network meta‐analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause},
  author={Grammati Sarri and Henry C. Pedder and Sofia Dias and Y Guo and Marilyn Lumsden},
  journal={BJOG: An International Journal of Obstetrics \& Gynaecology},
  pages={1514 - 1523}
Vasomotor symptoms (VMSs) are the hallmarks of menopause, occurring in approximately 75% of postmenopausal women in the UK, and are severe in 25%. 


The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women

Hormone replacement therapy (HRT) is the most commonly used treatment for managing menopausal symptoms and has been shown to be the most effective intervention in this context. The decision whether

British Menopause Society consensus statement on the management of estrogen deficiency symptoms, arthralgia and menopause diagnosis in women treated for early breast cancer

This guidance document by the British Menopause Society provides an overview of the management of women experiencing estrogen deficiency symptoms and arthralgia following a breast cancer diagnosis.

A dietary intervention for vasomotor symptoms of menopause: a randomized, controlled trial.

A dietary intervention consisting of a plant-based diet, minimizing oils, and daily soybeans significantly reduced the frequency and severity of postmenopausal hot flashes and associated symptoms.

The Women's Study for the Alleviation of Vasomotor Symptoms (WAVS): a randomized, controlled trial of a plant-based diet and whole soybeans for postmenopausal women

The combination of a low-fat, vegan diet and whole soybeans was associated with reduced frequency and severity of hot flashes and improved quality of life in vasomotor, psychosocial, physical, and sexual domains in postmenopausal women.

Modern approaches to the management of menopause

An analytical review of modern publications highlighting modern approaches to improving the quality and increasing life expectancy in postmenopausal women finding MHT the most effective treatment for symptom relief is carried out.

Effectiveness of transdermal oestradiol and natural micronised progesterone for menopausal symptoms.

  • Louise R NewsonA. Lass
  • Medicine
    The British journal of general practice : the journal of the Royal College of General Practitioners
  • 2018
The role of hormone replacement therapy (HRT) in the management of menopausal symptoms is discussed, and the advantages of different types and preparations of HRT are considered, based on the current medical evidence.

Progesterone for treatment of symptomatic menopausal women

  • J. Prior
  • Medicine, Biology
    Climacteric : the journal of the International Menopause Society
  • 2018
Evidence is highlighted that oral micronized progesterone (progesterone) is effective for hot flushes and night sweats, improves sleep and is likely safe in menopausal women (who are more than 1 year since last menstruation).



Soy extract phytoestrogens with high dose of isoflavones for menopausal symptoms

  • A. Ferrari
  • Medicine, Biology
    The journal of obstetrics and gynaecology research
  • 2009
Aim:  The aim of the present study was to assess the efficacy and safety of a standardized compound based on an extract of soy phytoestrogens, with high doses of isoflavones in the management of

Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.

Among healthy women, the use of escitalopram (10-20 mg/d) compared with placebo resulted in fewer and less severe menopausal hot flashes at 8 weeks of follow-up.

Effects on menopausal symptoms and acceptability of isoflavone-containing soy powder dietary supplementation

Powdered energy drinks are not commonly consumed in Australia and were poorly tolerated in this study, suggesting that other methods of isoflavone delivery may be more appropriate in this culture, in future trials.

Tibolone and low‐dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability

This study compared the vaginal bleeding pattern during administration of tibolone and low‐dose continuous combined estradiol plus norethisterone acetate (E2/NETA) to test efficacy on vasomotor symptoms and vaginal atrophy.

Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial

BZA 20 mg paired with CE 0.45 or 0.625 mg is effective, with short-term safety, for treating vasomotor symptoms in postmenopausal women.

Duration of menopausal vasomotor symptoms over the menopause transition.

Frequent VMS lasted more than 7 years during the menopausal transition for more than half of the women and persisted for 4.5 years after the FMP, and they may last longer for African American women.

Soy protein and isoflavone effects on vasomotor symptoms in peri- and postmenopausal women: the Soy Estrogen Alternative Study

It is suggested that soy protein containing 42 or 58 mg of isoflavones is no more effective than is oflavone-extracted soy protein for improving the number and severity of vasomotor symptoms in peri- and postmenopausal women.

Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial.

Paroxetine CR may be an effective and acceptable alternative to hormone replacement and other therapies in treating menopausal hot flash symptoms.

Phyto-Female Complex for the relief of hot flushes, night sweats and quality of sleep: Randomized, controlled, double-blind pilot study

  • C. RotemB. Kaplan
  • Medicine
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2007
Phyto-Female Complex is safe and effective for the relief of hot flushes and sleep disturbances in pre- and postmenopausal women, at least for 3 months' use.